Ropes & Gray Reps Genzyme In $700M Deal For Alnylam Stake
Genzyme Corp. will shell out $700 million for a 12 percent stake in biotechnology firm Alnylam Pharmaceuticals Inc. and greater rights to emerging products for rare diseases, the Massachusetts companies announced...To view the full article, register now.
Already a subscriber? Click here to view full article